Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021

NEXT STORY
Pfizer to Acquire Trillium Therapeutics Inc.
PREV STORY
Lexicon’s Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation

author_avatar
NASDAQ Market News

Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial Pneumonia (CABP) Treatment Guidelines

author_avatar
NASDAQ Market News

CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property

ZUG, Switzerland and CAMBRIDGE, Mass., March 26, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), ...

author_avatar
NASDAQ Market News